A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

The anti-obesity drug Zepbound made by Eli Lilly & Co. could be one of the biggest cost drivers for health insurers and ...

Some people taking Zepbound may notice a small amount of weight loss within 4 weeks, but most studies examining weight loss outcomes have reported results after longer periods, such as 52 or 72 weeks.

According to key opinion leaders, positive SURMOUNT-5 results, alongside Lilly’s business strategy, means Zepbound is set to ...

Arizona couple Michael and Julie Carroll have lost a combined 177 lbs. on a GLP-1 weight loss drug. 'It gave me my ...

The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...

The Food and Drug Administration approved Eli Lilly’s weight-loss drug Zepbound on Dec. 27 to treat sleep apnea, a common but ...

In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their ...

Wegovy and Ozempic are the exact same drug: semaglutide. They are dosed slightly differently and marketed for different ...

The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...

What a year! What do you think was the most important news in the United States in 2024? This list probably doesn’t reflect that. Rather, it shows what you, the readers, were looking at on ...